Acrivon therapeutics to participate in a panel discussion at the td cowen 44th annual health care conference

Watertown, mass., feb. 27, 2024 (globe newswire) -- acrivon therapeutics, inc. (“acrivon” or “acrivon therapeutics”) (nasdaq: acrv), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, acrivon predictive precision proteomics (ap3), today announced the company's president and chief executive officer, peter blume-jensen, m.d., ph.d., will participate in a panel entitled “gynecological cancers corporate panel discussion” on tuesday, march 5, 2024 at 10:30 a.m. et at the td cowen 44th annual health care conference in boston, ma.
ACRV Ratings Summary
ACRV Quant Ranking